Drugs / BCD101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07282145 | Sep 2025 overdue | essential hypertension | Bichedam Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282145 ↗ |
| Route | Oral | “A liquid formulation of BCD101 containing 2 g of the active ingredient per 10 g sachet, administered orally.” NCT07282145 ↗ |